



Working Paper

ISAAC M. OPPER

# From LATE to ATE

---

A Bayesian Approach

RAND working papers are intended to share researchers' latest findings and to solicit informal peer review. They have been approved for circulation by RAND Education and Labor but have not been formally edited or peer reviewed. Unless otherwise indicated, working papers can be quoted and cited without permission of the author, provided the source is clearly referred to as a working paper. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors. **RAND**® is a registered trademark. Learn more at [www.rand.org](http://www.rand.org).

For more information on this publication, visit [www.rand.org/t/WRA2499-1-v2](http://www.rand.org/t/WRA2499-1-v2).

#### **About RAND**

The RAND Corporation is a research organization that develops solutions to public policy challenges to help make communities throughout the world safer and more secure, healthier and more prosperous. RAND is nonprofit, nonpartisan, and committed to the public interest. To learn more about RAND, visit [www.rand.org](http://www.rand.org).

#### **Research Integrity**

Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit [www.rand.org/about/research-integrity](http://www.rand.org/about/research-integrity).

RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.

Published by the RAND Corporation, Santa Monica, Calif.

© 2023 RAND Corporation

RAND® is a registered trademark.

#### **Limited Print and Electronic Distribution Rights**

This publication and trademark(s) contained herein are protected by law. This representation of RAND intellectual property is provided for noncommercial use only. Unauthorized posting of this publication online is prohibited; linking directly to its webpage on [rand.org](http://rand.org) is encouraged. Permission is required from RAND to reproduce, or reuse in another form, any of its research products for commercial purposes. For information on reprint and reuse permissions, please visit [www.rand.org/pubs/permissions](http://www.rand.org/pubs/permissions).

# From LATE to ATE: A Bayesian Approach\*

Isaac M. Opper<sup>†</sup>

December 18, 2023

## Abstract

We develop a Bayesian model that produces a posterior distribution of the marginal treatment effect (MTE) function. The method can be used even when the MTEs are not identified – as is the case in RCTs with imperfect compliance – thereby allowing researchers to generate plausible ranges for important and potentially policy-relevant (but unidentified) quantities of interest. We then use the model to propose a natural decomposition of the posterior variance into “statistical uncertainty,” i.e., uncertainty that is due to the imprecise estimation of the observed moments, and “extrapolation uncertainty,” i.e., uncertainty that is due to the non-identifiability of the parameter of interest. We conclude by showing that under our preferred priors, even in an experiment as large as the Oregon Health Insurance Experiment, the main source of uncertainty in the ATE comes from uncertainty in the true values of the observed moments.

*Keywords:* marginal treatment effects; Bayesian models; instrumental variables; compliers; Gaussian process

*JEL Classification:* C11; C26

---

\* I am very thankful to Aarya Suryavanshi, who took the lead in developing the R package, and to Joshua Eagan who helped QA the code. An R package to implement the method and replicate the empirical results is available at <https://github.com/isaacopper/BayesianMTEs>. I’m also thankful to Stephanie Rennane and Jessie Cox, who both provided valuable feedback on an early draft, as well as Lisa Jaycox for all her help, support, and patience during my particularly challenging – and not particularly on-time – RIR. Finally, the comments I initially received from two anonymous referees, the AE, and editor truly transformed the paper and I am grateful for their careful read and thoughtful comments. Funding for this research was provided by gifts from RAND supporters and income from operations.

<sup>†</sup> RAND Corporation. Email: [iopper@rand.org](mailto:iopper@rand.org).

# I Introduction

Imperfect compliance is pervasive in randomized control trials (RCTs): some individuals assigned to the treatment group will inevitably not follow through with the treatment and some individuals assigned to the control group will often find a way to receive the treatment despite their initial assignment. A key question in the evaluation of RCTs is therefore how to handle imperfect compliance, which is often done by using the treatment assignment as an instrument for treatment status and employing an instrumental variables (IV) design.

One downside of the IV design is that – even when the identification assumptions are all met – the resulting treatment effects are only valid locally, resulting in what is commonly referred to as the local average treatment effect (LATE) (Imbens and Angrist, 1994). In an RCT with imperfect compliance, for example, that means that the resulting estimates represent the average treatment effect on the set of individuals whose treatment status is impacted by instrument, i.e., who enroll in the treatment if and only if they are assigned to it. This group is often referred to as the set of “compliers” and the LATE is sometimes called the CATE, for complier average treatment effect.

While the LATE is often an important parameter of interest, it is rarely the only parameter of interest (Heckman and Vytlacil, 2001). It would also be valuable, for example, to know what the effect of the treatment was on individuals who enrolled regardless of their treatment assignment or to know the average effect on the entire population. Unfortunately, with a binary instrument these averages are not identified without additional strong assumptions on how individuals select into treatment (e.g., Brinch et al. (2017); Kowalski (2023)), which has led to a large literature on ways to estimate bounds on the estimands of interest (e.g., Manski (1990); Balke and Pearl (1997); Bhattacharya et al. (2008); Mogstad et al. (2018)).

Rather than attempt to identify or bound the estimands, we develop a Bayesian model in this paper.<sup>1</sup> Like many existing approaches, we start with a generalized Roy model in which individuals have different propensities to self-select into treatment. Key to this model are two functions: one that illustrates how individuals’ untreated outcome varies with their implied cost of enrolling in the treatment and the other

---

<sup>1</sup>Other recent work that uses a Bayesian model in the RCT context has focused on combining estimates from multiple contexts or estimating distributional effects, rather than extrapolating from the LATE to ATE, e.g., Meager (2019, 2022); Gechter and Meager (2022).

which illustrates how the treatment’s effect on individuals’ outcomes varies with their implied cost of enrolling. The second of these functions is usually referred to as the marginal treatment effect (MTE) function and from which one can construct most estimands of interest (Heckman and Vytlačil, 2007a,b). Rather than viewing these functions as fixed, however, we assume that the functions themselves are generated probabilistically. By using a Gaussian process to place a prior distribution on these functions, we can capture the belief – prevalent in data science and machine learning – that smooth functions are more likely than functions that oscillate wildly.

We then show that the generalized Roy model, the Gaussian process, and the observed moments can be combined in a straightforward way to output a posterior distribution of the MTE function and therefore of most estimands of interest. One advantage of the model is that it allows us to explicitly quantify how uncertain the estimates are for traditionally unidentified treatment effects – such as the average treatment effect (ATE), always taker average treatment effect (ATATE), and never taker average treatment effect (NTATE) – in a way that accounts for both uncertainty in the unobserved moments and uncertainty in how one should extrapolate away from the observed moments. While the posterior variance captures both sources of uncertainty, we also highlight how the model permits a natural decomposition of the posterior variance into “statistical uncertainty,” i.e., uncertainty that is due to the imprecise estimation of the observed moments, and “extrapolation uncertainty,” i.e., uncertainty that is due to the non-identifiability of the full MTE function.

We next turn to questions of implementation. After illustrating how the hyperparameters of the model govern the distribution of potential MTE functions and specifying our preferred hyperprior, i.e., prior distribution over these hyperparameters, we use data from the Oregon Health Insurance Experiment (OHIE) to explore how the model works in practice. We first show that our specification of the hyperprior is important, since the hyperparameters of the model are poorly identified (at least in cases like the OHIE where there is a single binary instrument). In contrast, the observed moments provide important information about even the unidentified treatment effects; for example, the posterior variance of the ATE is 93% smaller than the prior variance of the ATE. To better understand where the remaining uncertainty stems from, we use the proposed decomposition of overall uncertainty into extrapolation and statistical uncertainty; in doing so, we show that under our preferred hyperprior the extrapolation uncertainty is much less important than the statistical

uncertainty, even in an RCT as large as the OHIE and one in which a large fraction of the population are never-takers.

## II Defining the Bayesian Hierarchical Model

We start by describing the two building blocks of our approach: the generalized Roy model and Gaussian processes. Both have been studied extensively and the purpose of Section II.A and II.B is to ensure the reader starts with the necessary background and to clarify our notation, rather than to introduce any new ideas. For the interested reader, see Heckman (2010) (among others) for more discussion about the generalized Roy model and Rasmussen and Williams (2006) for more details about Gaussian processes. We then discuss how the two building blocks can be naturally combined to into a Bayesian hierarchical model and how the resulting Bayesian hierarchical model relates to other commonly used models.

### II.A Generalized Roy Model

We consider the effect of a binary treatment on a single outcome. We assume that each individual is defined by three latent variables: their outcome if they are not treated, the effect that the treatment has on their outcome, and their implied cost of enrolling in the treatment; we denote these as  $\mu_i$ ,  $\tau_i$ ,  $\eta_i$ , respectively. In other words, we use  $\mu_i$  to denote individual  $i$ 's outcome in the absence of treatment and  $\tau_i$  to denote the causal effect of the treatment on individual  $i$ 's outcome; clearly  $\mu_i + \tau_i$  is then their outcome if they are treated.

The researcher does not observe these three latent variables and instead observes each individuals' outcome, treatment status, and an instrument; we denote these as,  $Y_i$ ,  $T_i$ , and  $Z_i$ , respectively. For simplicity, we focus here on case without any additional  $X_i$  covariates, although the model can be extended to included these. Given  $T_i$ , we can write the observed outcome as a function of the latent variables without further assumptions as follows:  $Y_i = \mu_i + \tau_i T_i$ . The restrictions to the model appear in how we relate the latent variables to the treatment status. To do so, we assume that we can relate  $\eta_i$  and  $Z_i$  to treatment status via a threshold-crossing representation, i.e.,:

$$T_i = \mathbf{1}(\nu(Z_i) \geq \eta_i) \tag{1}$$

for some (unknown) function of the instrument  $\nu(Z_i)$ . As is common, we will assume that  $\eta_i$  is continuously distributed, which means without loss of generality we can normalize this distribution to be uniform between zero and one. Note that individuals with higher  $\eta_i$  are less likely to enroll in the treatment, i.e., have a higher implied cost of enrolling in the treatment. In doing so, it then follows that  $\nu(Z_i) = \mathbb{E}[T_i|Z_i]$ , which hints at how we can estimate  $\nu$ . Finally, we will assume that  $(\mu_i, \tau_i, \eta_i) \perp\!\!\!\perp Z_i$ . This assumption captures the idea that  $Z_i$  is a valid instrument, in that it only affects the outcomes by affecting the likelihood that an individual is treated.<sup>2</sup>

We then define the following two conditional moments, which we assume exist and serve as the objects of interest:

$$\tau(\eta) = \mathbb{E}[\tau_i|\eta_i = \eta] \quad \text{and} \quad \mu(\eta) = \mathbb{E}[\mu_i|\eta_i = \eta] \quad (2)$$

The first function  $\tau(\eta)$ , in particular, is the marginal treatment effect (MTE) as defined in Heckman and Vytlacil (1999, 2005) and others. Again, implicit in these definitions is the IV assumption, that once we condition on  $\eta$ , we do not need to condition on  $Z$ . More specifically, the assumption is that  $\mathbb{E}[\tau_i|\eta_i = \eta, Z_i = Z] = \mathbb{E}[\tau_i|\eta_i = \eta]$  for all  $Z$ , with a similar expression for  $\mu_i$ .

In addition, we define two additional conditional moments as follows:

$$y_0(\eta) = \mathbb{E}[\mu_i|\eta_i > \eta] \quad \text{and} \quad y_1(\eta) = \mathbb{E}[\mu_i + \tau_i|\eta_i \leq \eta] \quad (3)$$

Defining four sets of conditional moments is redundant, in that the functions defined in Equation (2) would imply the value of the functions in Equation (3) and vice versa. Most useful for our purposes, we can relate  $y_0$  and  $y_1$  to  $\tau$  as follows:

$$\mathbb{E}[\tau(\eta)|\eta \in (\underline{\eta}, \bar{\eta})] = \frac{1}{\bar{\eta} - \underline{\eta}} \cdot \begin{bmatrix} \bar{\eta} \\ -\underline{\eta} \\ 1 - \bar{\eta} \\ -(1 - \underline{\eta}) \end{bmatrix}' \cdot \begin{bmatrix} y_1(\bar{\eta}) \\ y_1(\underline{\eta}) \\ y_0(\bar{\eta}) \\ y_0(\underline{\eta}) \end{bmatrix} \quad (4)$$

Note that while  $y_0(\eta)$  conditions on  $\eta_i$  being larger than  $\eta$ ,  $y_1(\eta)$  conditions on  $\eta_i$

---

<sup>2</sup>We do not explicitly assume that  $Z_i$  is related to  $T_i$ , or in our model that  $\nu(Z_i)$  varies with  $Z_i$ , which is often included as the second condition that  $Z_i$  is a valid instrument. This is because the proposed method will be valid even in this case, it is just uninteresting since the resulting lack of variation makes the posterior generally uninformative.

being smaller than  $\eta$ . The reasons for this peculiar conditioning is that it makes  $y_0$  and  $y_1$  more directly reflect the values we actually observe in the data, which – as we will explain below – will be quite useful.

## II.B Gaussian Process Prior

While there are multiple ways to define a Gaussian process, for our purposes the most useful definition is taken from Rasmussen and Williams (2006):

**Definition (Rasmussen and Williams, 2006) 1.** *A Gaussian process (GP) is a collection of random variables, any finite number of which have a joint Gaussian distribution.*

To highlight how a GP is useful in our context, let's restrict our attention to the MTE function  $\tau(\eta)$  and denote  $\mathcal{T}$  as the space of potential MTE functions. It is intuitive to imagine placing a prior distribution over the various functions  $\tau \in \mathcal{T}$ , which governs how likely any one function is to be drawn at random from  $\mathcal{T}$ . Any function  $\tau$  is simply defined by its value at every point  $\eta$  in its domain, and so an equivalent formulation is to consider each point  $\tau(\eta)$  as its own random variable; one draw of  $\tau \in \mathcal{T}$  is therefore equivalent to one draw from an infinite number of (potentially correlated) random variables  $\tau(\eta)$ . A consequence of this is that defining how the random variables  $\tau(\eta)$  themselves co-vary is an alternative way of defining how likely it is to draw a particular function  $\tau$ , i.e., to define our prior distribution of functions.

The GP is a common way to specify the covariance and hence the prior distribution over functions. We can define the GP prior by the mean and covariance function. For example, consider some GP that models the relationship between  $x_i$  and  $y_i$  and then let  $m(x_i)$  and  $k(x_i, x'_i)$  be the mean and covariance functions, respectively. One of the main advantages of a GP is that with a GP it is quite easy to transition from the prior distribution over functions, defined implicitly by  $m(x_i)$  and  $k(x_i, x'_i)$ , to the posterior distribution over functions after one conditions on a set of observations. For example, suppose we observe a single observation  $(y_i, x_i)$  and assume for now that there is no additional error term so  $y_i = f(x_i)$  for some function  $f$ . Then from the



definition of a GP, it clearly follows that:

$$f(x')|y_i, x_i = N\left(\mu, \sigma^2\right) \quad \text{with}$$

$$\mu = m(x') + \frac{k(x_i, x')}{k(x_i, x_i)}(f(x_i) - m(x_i)) \quad \text{and} \quad \sigma^2 = k(x', x') - \frac{k(x_i, x')^2}{k(x_i, x_i)}$$

for any  $x'$ . We can write a similar expression if we observe multiple observations and/or want to generate posterior predictions at multiple points on the domain of  $f$ .

## II.C Bayesian Hierarchical Model

We now combine the two building blocks to specify the full Bayesian hierarchical model. To do so, we add to the Generalized Roy model the assumption that the functions  $\tau(\eta)$  and  $\mu(\eta)$  themselves follow a Gaussian process. Specifically, we have that:

$$\text{Gaussian process for } \mu: \quad \mu(\eta)|\theta_\mu \sim \mathcal{GP}(0, k_\mu(\eta, \eta'|\theta_\mu)) \quad (5)$$

$$\text{Gaussian process for } \tau: \quad \tau(\eta)|\theta_\tau \sim \mathcal{GP}(0, k_\tau(\eta, \eta'|\theta_\tau)) \quad (6)$$

for known covariance functions (or kernels)  $k_\mu(\eta, \eta'|\theta_\mu)$  and  $k_\tau(\eta, \eta'|\theta_\tau)$  with hyperparameters  $\theta_\mu$  and  $\theta_\tau$ . In the next sections, we discuss the choice of the covariance functions and hyperparameters, but for now will take those as given and only make the assumption that the covariance functions imply that the process is sample-continuous, i.e., that every realization of  $\mu(\eta)$  and  $\tau(\eta)$  results in continuous functions. Rather than make the weakest assumption possible, we opt for a more readily interpretable sufficient condition regarding the covariance functions, stated below:

**Assumption 1.** *The covariance functions  $k_\mu(\eta, \eta'|\theta_\mu)$  and  $k_\tau(\eta, \eta'|\theta_\tau)$  are both Lipschitz continuous functions.*

We further assume that the outcomes also contain a normally distributed error term. Specifically, defining the error term  $\epsilon_i = Y_i - \mu(\eta) - \tau(\eta)T_i$  and letting  $\epsilon$  be the vector of all individuals' error terms, we assume that  $\epsilon \sim N(0, \Sigma)$  for some positive semi-definite matrix  $\Sigma$ . It is common to assume that the error term is distributed i.i.d., in which case  $\Sigma = \sigma_\epsilon^2 \mathbf{I}$  where  $\mathbf{I}$  is the identity matrix; however, we keep this more general form to highlight how the method can be used in cases where the errors are

not all independent, as would be the case in cluster randomized trials, for example. Finally, we note that the assumption that the error terms are distributed normally can be relaxed if one prefers take the asymptotic perspective and apply the central limit theorem to infer that the observed moments are approximately normal.

## II.D Discussion of the Model

To better understand the model’s assumptions and construction, it is helpful to use an alternative formulation of the Gaussian process. In particular, it is possible to think of the covariance functions as implying a mapping of  $\eta$  to a larger feature space and a set of priors on the coefficients in that feature space. For example, consider the basis expansion that maps  $\eta$  to  $\phi(\eta)' = [1, \eta, \eta^2, \eta^3]$  and a Bayesian linear regression specified as  $y = \phi(\eta)' \beta + \epsilon$  under a prior  $\beta \sim N(0, \Sigma_\beta)$  and a normally distributed and i.i.d. error term. While formulated quite differently, this is equivalent to a Gaussian process with a covariance function specified as:  $k(\eta, \eta') = \phi(\eta)' \Sigma_\beta \phi(\eta')$ .

This formulation makes clear that the model described in Section II.C nests other models which extrapolate away from the observed moments via linear (Kowalski (2023)), polynomial (Brinch et al. (2017)), or structural (Kline and Walters (2019)) assumptions. While these assumptions are at times palatable, there are other times when the researcher may be uncomfortable making the assumption that, for example, the MTE function is necessarily linear, but still wants to say something about policy-relevant parameters beyond the LATE. By using a Bayesian framework, the model allows researchers to relax the assumptions imposed on the MTE and  $\mu(\eta)$  functions and still generate the posterior distributions of the non-identified parameters. We should highlight explicitly, however, that there is “no Bayesian free lunch” (Poirier (1998)) and while the model does allow researchers to relax the assumptions imposed set of potential functions, it still requires the researchers to make an assumption (implicit in the choice of the covariance specification) about which functions are more or less likely.

This formulation also helps illustrate how the choice of covariance function implicitly places priors on the how the likelihood of functions in  $\mathcal{T}$  is related to how smooth they are in  $\eta$ . While we looked at a specific example above, from Mercer’s theorem it is always possible to associate the covariance function with a (possibly infinite dimensional) feature space  $\phi(\eta)$  and prior on the error terms. In particular, while we

will not cover the details here, the squared exponential covariance function that we use for our empirical analysis implies an infinite dimensional feature space  $\phi(\eta)$  that consist of mappings of the form  $\phi_n(\eta) = \exp(-\alpha\eta^2)H_n(\beta\eta)$  where  $H_n$  is  $n^{\text{th}}$  order Hermite polynomial and  $\alpha$  and  $\beta$  are constants that depend on the hyperparameters of the squared exponential covariance function. Crucially, the variance of the priors for  $\phi_n(\eta)$  are decreasing in  $n$ , which implies that the impact of the higher order (and therefore more oscillating) terms on the resulting function are minimized, leading to a smooth function.

### III Implications of the Bayesian Hierarchical Model

Having fully specified the model in the above section, we now turn to an analysis of the general model. We first discuss how it can be used to create posteriors of the MTE function and other estimands of interest, and then highlight how the model allows one to decompose the uncertainty in the resulting estimates into uncertainty that is due to imprecise estimation of the observed moments and uncertainty that is due to the required extrapolation away from these observed moments.

#### III.A Bayesian Posterior of the MTE

To generate posterior predictions we have to grapple with the fact that we do not directly observe  $\tau(\eta)$  or  $\mu(\eta)$  at any point  $\eta$ . Instead, we observe the functions  $y_0(\eta)$  and  $y_1(\eta)$ , and only do so at points  $\eta$  in the image of  $\nu(Z_i)$ . Luckily, if  $\tau(\eta)$  and  $\mu(\eta)$  are both GPs, then together  $y_0(\eta)$  and  $y_1(\eta)$  form one large Gaussian process. Formally, define  $y_1(\eta)$  and  $y_0(\eta)$  as in Equation (3) and let:

$$\tilde{y}(t, \eta) = ty_1(\eta) + (1 - t)y_0(\eta) \tag{7}$$

for  $t \in \{0, 1\}$ . We then have the following remark, which we prove in Appendix A.

**Remark 1.** *Under the the Bayesian hierarchical model defined in Section II and Assumption 1,  $\tilde{y}(t, \eta)$  as defined in Equation (7) also follows a mean-zero Gaussian process with a covariance function – denoted  $k_{\tilde{y}}$  – that depends on  $k_{\mu}(\eta, \eta' | \theta_{\mu})$  and*

$k_\tau(\eta, \eta'|\theta_\tau)$ . In particular, we have that:

$$k_{\tilde{y}}((t, \eta), (t', \eta')|\theta_\mu, \theta_\tau) = \begin{cases} \mathbb{E}[k_\mu(\tilde{\eta}, \tilde{\eta}'|\theta_\mu) + k_\tau(\tilde{\eta}, \hat{\eta}|\theta_\tau)|\tilde{\eta} \leq \eta, \tilde{\eta}' \leq \eta'] & \text{if } t = t' = 1 \\ \mathbb{E}[k_\mu(\tilde{\eta}, \tilde{\eta}'|\theta_\mu)|\tilde{\eta} > \eta, \tilde{\eta}' > \eta'] & \text{if } t = t' = 0 \\ \mathbb{E}[k_\mu(\tilde{\eta}, \tilde{\eta}'|\theta_\mu)|\tilde{\eta} > \eta, \tilde{\eta}' \leq \eta'] & \text{if } t = 0 \neq t' \\ \mathbb{E}[k_\mu(\tilde{\eta}, \tilde{\eta}'|\theta_\mu)|\tilde{\eta} \leq \eta, \tilde{\eta}' > \eta'] & \text{if } t = 1 \neq t' \end{cases} \quad (8)$$

As mentioned, the fact that  $\tilde{y}(t, \eta)$  is generated via a Gaussian process is helpful because that corresponds directly to what is observed by the researcher. To more fully highlight why this is helpful, denote  $Y^{obs}$  to be the vector of observed outcomes and consider a finite vector  $\tilde{Y}'$  of potentially observed conditional moments. For example, we could have  $\tilde{Y}$  be:

$$\tilde{Y}' = [y_0(0), y_0(\Delta), \dots, y_0(1 - \Delta), y_0(1), y_1(0), y_1(\Delta), \dots, y_1(1 - \Delta), y_1(1)] \quad (9)$$

for some arbitrarily small step size  $\Delta$ . From Remark 1, we get then get that:

$$\tilde{Y} \sim N(0, K_{\tilde{Y}}) \quad (10)$$

where  $K_{\tilde{Y}}$  is a matrix that can be inferred by the covariance functions  $k_\mu(\eta, \eta'|\theta_\mu)$  and  $k_\tau(\eta, \eta'|\theta_\tau)$ . In particular, if the  $i^{th}$  row of  $\tilde{Y}$  is  $y_t(\eta)$  and the  $j^{th}$  row of  $\tilde{Y}$  is  $y_{t'}(\eta')$ , the the  $(i, j)^{th}$  element of  $K_{\tilde{Y}}$  is  $k_{\tilde{y}}((t, \eta), (t', \eta'))$ . We also get that

$$Y^{obs} \sim N(0, K_{Y^{obs}} + \Sigma) \quad (11)$$

where  $K_{Y^{obs}}$  is defined similarly to  $K_{\tilde{Y}}$  and  $\Sigma$  is the variance of the error term (as defined in Section II). Finally, define  $K_{\tilde{Y}, Y^{obs}}$  such that if  $i^{th}$  row of  $\tilde{Y}$  is  $y_t(\eta)$  then the  $(i, j)^{th}$  element of  $K_{\tilde{Y}, Y^{obs}}$  is  $k_{\tilde{y}}((t, \eta), (T_j, \nu(Z_j)))$ .

Given these matrices, we can derive the Bayesian posterior of  $\tilde{Y}$  as stated below:

**Remark 2.** *The Bayesian posterior of  $\tilde{Y}$  given the observed data:*

$$\tilde{Y}|Y^{obs} \sim N(\mu_{\tilde{Y}}, \Sigma_{\tilde{Y}}) \quad (12)$$

where

$$\mu_{\tilde{Y}} = K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}} + \Sigma)^{-1} Y^{obs} \quad (13)$$

$$\Sigma_{\tilde{Y}} = K_{\tilde{Y}} - K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}} + \Sigma)^{-1} K'_{\tilde{Y}, Y^{obs}} \quad (14)$$

One nice thing about this expression is that posterior described above gives a closed-form solution to quantify how much is learned from the data (as opposed to reflecting the prior). In particular, one way to summarize this is through  $Var(\tilde{Y}) - Var(\tilde{Y}|Y^{obs})$ , i.e., how much posterior variance shrinks relative to the prior variance, which from above can be expressed as  $K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}} + \Sigma)^{-1} K'_{\tilde{Y}, Y^{obs}}$ .

Finally, note that although the expressions above give the posterior of  $\tilde{Y}$  rather than  $\tau(\eta)$ , since  $\tau(\eta)$  is a continuous function the expression can be combined with Equation (4) to generate Bayesian posteriors of the marginal treatment effect function and hence any target parameter of interest, e.g., the average treatment effect, the average treatment on the treated, or average treatment on the controls.<sup>3</sup>

### III.B Understanding the Sources of Uncertainty

Broadly speaking, there are two sources of uncertainty in the estimates: statistical uncertainty, which stems from the fact that the true values of the observed moments are unknown due to the finite sample size and extrapolation uncertainty, which stems from the fact that we may want to extrapolate away from these moments to generate estimates of various unidentified average effects such as ATE, Always Taker ATE (ATATE), and Never Taker ATE (NTATE). In fact, much of the initial motivation for Bayesian approach developed here was to generate a continuous measure of extrapolation uncertainty, rather than have it be zero for the identified estimand (i.e., LATE) and infinite for unidentified estimands (i.e., ATE, ATATE, and NTATE). We now formally define “statistical uncertainty” and “extrapolation uncertainty” to allow for researchers to identify which (if any) source dominates the overall uncertainty measures.

From the above intuition, it follows that extrapolation uncertainty can be thought of as the variance of the posteriors in the (hypothetical) case where the observed

---

<sup>3</sup>The continuity of  $\tau(\eta)$  is a consequence of Assumption 1 and ensures that we can approximate the function with a finite grid, where each point represents the average treatment effect within a small window.

moments are known with certainty. Note that in the model, this corresponds precisely to the case in which  $\Sigma$  vanishes, which we can use along with Equation (14) to compute the extrapolation uncertainty. We can similarly define the statistical uncertainty as the variance of the posteriors that is due to the fact that the observed moments are measured with noise.<sup>4</sup> Formally, we define these as follows:

$$\Sigma_{extrap} = K_{\tilde{Y}} - K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}})^{-1} K'_{\tilde{Y}, Y^{obs}} \quad (15)$$

$$\Sigma_{stat} = K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}}^{-1} - (K_{Y^{obs}} + \Sigma)^{-1}) K'_{\tilde{Y}, Y^{obs}} \quad (16)$$

To more better motivate these expressions, we document a number of properties about the uncertainty measures in the following remark.

**Remark 3.** Define  $\Sigma_{\tilde{Y}}$  as in Equation (14) and  $\Sigma_{extrap}$  and  $\Sigma_{stat}$  as in Equations (15)-(16). Then we have the following:

- Both  $\Sigma_{extrap}$  and  $\Sigma_{stat}$  are positive semi-definite matrices.
- If  $\Sigma = 0$ , then  $\Sigma_{stat} = 0$ .
- Let  $\tau$  be some estimand of interest and define  $\tilde{Y}$  to be the set of observations needed to calculate  $\tau$ . Then  $\Sigma_{extrap} = 0$  if  $\tau$  is identified given the observed data.
- Extrapolation and statistical uncertainty combine to equal the overall uncertainty, e.g.,  $\Sigma_{\tilde{Y}} = \Sigma_{extrap} + \Sigma_{stat}$

The first property – that the measures are all positive semi-definite matrices – simply highlights that they can be considered valid measures of uncertainty. The next helps justify the fact that we refer to  $\Sigma_{stat}$  as the “statistical uncertainty” by noting that it, as well as the frequentist measure of uncertainty defined below, are zero if the observed moments are known with certainty. Similarly, the third helps justify why we refer to  $\Sigma_{extrap}$  as the “extrapolation uncertainty,” by highlighting that it stems from the the lack of identification.

There is some subtlety in the third statement since identification is fundamentally an asymptotic statement, e.g., with enough data we would be able to estimate the

---

<sup>4</sup>In a previous version of the paper, we defined statistical uncertainty in the way we currently define frequentist uncertainty (as defined below) and used  $\Sigma_{stat}$  to denote this measure. We apologize for the major change in terminology and notation, but feel this version better captures the concepts.

underlying functions with near perfect precision, while  $\Sigma_{extrap}$  is defined for any sample size. Here, the problem with a finite sample size does not stem from the fact that the outcomes are measured with noise, but from the fact that only a finite number of points in the domain of  $y_0$  and  $y_1$  are observed. For example, under an assumed sampling scheme where individuals are sampled randomly with  $Z_i \sim U(0, 1)$  and  $\nu(Z_i) = Z_i$ , the functions  $y_0$  and  $y_1$  would be non-parametrically identified, but still potentially require substantial extrapolation if the sample size is only 10 individuals. This is the motivation behind the statement that “ $\tau$  is identified *given the observed data.*” Roughly, “identification given the observed data” is a finite sample statement about having enough unique points in the domain of the observed sample, while traditional frequentist identification is an asymptotic statement about both observing enough unique points in the domain and having enough observations at (or almost at) each point to know the true moments with arbitrary precision. We leave the formal definition of this statement, as well as some additional motivation and connection between the two identification concepts to Appendix A, where we also include the formal proofs of all the statements in Remark 3.

Finally, the fourth statement then highlights that the statistical uncertainty and extrapolation uncertainty serve as a true decomposition of the overall uncertainty, in that the sum to the two sources of uncertainty equal to the overall uncertainty.

We also find it useful to define the “frequentist uncertainty,” which we define as the variance of the maximum a posteriori (MAP) estimates, i.e., of  $\mu_{\tilde{Y}}$ , that is due to uncertainty in the observed moments stemming from the error term. This corresponds to the conventional standard error estimates under a frequentist approach where, for example, the formula for  $\mu_{\tilde{Y}}$  is motivated as a regularized basis expansion rather than via a Bayesian model (e.g., see Chapter 5 in Hastie et al. (2009)). Using Equations 13 and 14 along with the fact that  $Var(Y^{obs}|\mu, \tau) = \Sigma$ , it is easy to derive the fact that this corresponds to:

$$\Sigma_{freq} = K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}} + \Sigma)^{-1} \Sigma (K_{Y^{obs}} + \Sigma)^{-1} K'_{\tilde{Y}, Y^{obs}} \quad (17)$$

With this definition, we can compare the statistical uncertainty in this model to the traditional frequentist measures uncertainty, i.e., traditional standard errors. Interestingly, we show that our measure of statistical uncertainty is strictly larger than the traditional frequentist measure of uncertainty. The formal statement is

documented in the following remark:

**Remark 4.** Define  $\Sigma_{stat}$  as in Equation (16) and  $\Sigma_{freq}$  as in Equation (17). Then if  $\Sigma \neq 0$ , we have that  $\Sigma_{stat} - \Sigma_{freq}$  is a positive definite matrix.

Note that, along with the statements in Remark 3, this result implies that the standard deviation of the Bayesian posterior is strictly larger than traditional frequentist standard errors for any estimand of interest, i.e., any measure of  $\mathbb{E}[\tau(\eta)|\eta \in (\underline{\eta}, \bar{\eta})]$ , including identified ones such as the LATE.

## IV Implementation

In the above sections, we outlined the Bayesian hierarchical model and discussed both how it can be used to generate posterior estimates of the marginal treatment effects and other (generally unidentified) objects of interest and how it can allow for a better understanding of the sources of uncertainty in the resulting estimates. In doing so, we have been agnostic about the choice of the prior, i.e., the covariance function and the hyperparameters. Of course, this choice is quite important when implementing the method and so we now discuss the choice of covariance function and hyperprior (i.e., our imposed prior distribution over the hyperparameters that are associated with the chosen covariance function) that we use in the empirical examples in the next section and which are implemented in the associated R package. We then discuss the choice of whether to integrate over or estimate the hyperparameters and finally provide a sketch of the overall algorithm.

### IV.A Covariance Function and Hyperpriors

As mentioned above, in our empirical analysis below we will use the squared exponential to define the covariance. Specifically, this implies that:


$$k_{\mu}(\eta, \eta' | \theta_{\mu}) = \sigma_{\mu}^2 \exp\left(-\frac{(\eta - \eta')^2}{2l_{\mu}^2}\right) \quad \text{and} \quad k_{\tau}(\eta, \eta' | \theta_{\tau}) = \sigma_{\tau}^2 \exp\left(-\frac{(\eta - \eta')^2}{2l_{\tau}^2}\right) \quad (18)$$

This is a common choice when modeling Gaussian processes. Each covariate function has two hyperparameters:  $\sigma^2$  which controls the amplitude and  $l$  which is referred to as the lengthscale.



The amplitude ( $\sigma^2$ ) is simply a scale factor and is present in front of nearly every covariance function. The lengthscale ( $l$ ) is more unique to the squared exponential function form and, roughly speaking, determines how much the function oscillates. As a visual example, consider Panel (a) of Figure 1. In it, each panel illustrates three random  $\mu(\eta)$  functions generated by a Gaussian process with different lengthscales specified in the title. As can be seen, with lengthscales less than  $e^{-1}$  the random functions tend to oscillate widely, while with lengthscales greater than  $e^1$  the random functions are all virtually flat. It is worth noting, however, that the interpretation of the lengthscale is bit different if one instead considers the functions  $y_0(\eta)$  and  $y_1(\eta)$  instead of the functions  $\mu(\eta)$  and  $\tau(\eta)$ . In Panel (b) of Figure 1, we three random functions of  $y_0(\eta)$  under the different lengthscales as before. Since  $y_0(\eta)$  corresponds to the conditional average, we find that the resulting functions are smoother than the three random  $\mu(\eta)$  functions, at least for relatively small lengthscales.

Figure 1: Random Functions with Different Lengthscales



Note: These figure shows three random functions sampled from a Gaussian process with varying lengthscales and the same output variance, equal to 0.05. Panel (a) shows the functions  $\mu(\eta)$ , while panel (b) shows the resulting  $y_0(\eta)$  functions.

Of course, while above analysis suggests that the lengthscales are important parameters in the model, it does not answer the question of how they should be chosen. To define the two potential approaches, it will be useful to let  $\theta$  be the vector of hyperparameters – e.g., in our model:  $\theta = [l_\mu, l_\tau, \sigma_\mu, \sigma_\tau]'$ . We then can use  $p(\theta|Y, T, Z)$  to be the likelihood of  $\theta$  conditional on the data. (We will discuss shortly how  $p(\theta|Y, T, Z)$  can be calculated and what additional assumptions are needed to do so.)

There are then two potential approaches about how to handle the hyperparameters: to choose the hyperparameters that be best fit the data or to integrate over the hyperparameters that are consistent with the data. More precisely, the first, which we refer to as the “empirical Bayes approach” consists of choosing the vector of hyperparameters that maximizes the empirical likelihood, i.e.,  $\hat{\theta}^{EB} = \arg \max_{\theta} p(\theta|Y, T, Z)$ . The second approach, which we refer to as “the full Bayes approach,” samples from

the distribution  $p(\theta|Y, T, Z)$  estimating  $\mu_{\hat{\gamma}}$  and  $\Sigma_{\hat{\gamma}}$  for each sampled vector of hyperparameters, and then combining each estimate of these into the final estimate.

Clearly, both approaches require us to be able to compute  $p(\theta|Y, T, Z)$ . To do so, we note that from Bayes' law, we have that:

$$p(\theta|Y, T, Z) \propto p(Y|\theta, T, Z) \cdot p(\theta) \quad (19)$$

Furthermore, the values of  $p(Y|\theta, T, Z)$  comes directly from Equation (11), so the only object we need to know is  $p(\theta)$ . This is not something we can determine from the data and corresponds to the hyperprior, i.e., the priors over the hyperparameters. Thus, regardless of whether we employ an empirical Bayes or full Bayes approach, to complete the Bayesian hierarchical model, we need to specify how likely the hyperparameters are to have been the ones used to generate the data.

A seemingly appealing option is to choose a very diffuse prior with roughly equal weight on a wide-range of hyperparameters. This reflects the general preference to “let the data speak” rather than imposing – even inadvertently – the result through our initial assumptions on the data generating process. It is worth noting, however, that choosing a diffuse prior is itself an initial assumption. Our view is that we generally do have a prior belief that, for example, a monotonic MTE function is more likely than one with multiple peaks and valleys. Our preferred approach is to therefore to choose a hyperprior that suggests lengthscales in the middle row of Figure 1 are more likely than the lengthscales in either the top or bottom row. This is particularly important in the case where there is a single binary instrument; as highlighted in Appendix C, in this case the hyperparameters are poorly identified and so a diffuse prior could lead to the model implying a very restricted set of potential MTE functions.

Specifically, in the empirical example we specify that the hyperpriors take the form of a log-normal distribution as follows:

$$\log(l) \sim N(0, 0.5^2) \text{ and } \log(\sigma) \sim N(.5\log(\sigma_\epsilon), 1.5^2) \quad (20)$$

$$l_\mu = l_\tau \text{ and } \sigma_\mu = \sigma_\tau \quad (21)$$

where  $\sigma_\epsilon$  is the standard error of the residuals. Note that in this specification, we assume that the hyperparameters for the function  $k_\mu(\eta, \eta'|\theta_\mu)$  are the same as for the function  $k_\tau(\eta, \eta'|\theta_\tau)$ .

## IV.B Sketch of the Algorithm

We now describe the full algorithm we use to estimate the Bayesian MTEs, which we have outlined in psuedocode as Algorithm 1.

In the first step **Collapse Data** we calculate the average  $Y_i$  for every value of the instrument  $Z_i$  and every treatment status, i.e., to collapse the data into the observed moments. While the algorithm does not exactly require a discrete instrument, it assumes that there are multiple observations for each value of the instrument and for each treatment status because in the second step **Estimate Error**, it calculates  $\hat{\Sigma}$  as a diagonal matrix with the diagonals equal to:

$$\hat{\Sigma}_{k,k} = \frac{1}{N_k} \sum_{\forall i \text{ s.t. } (Z_i, T_i) = (Z, T)} \left( Y_i - \hat{\mathbb{E}}[Y_i | Z_i = Z, T_i = T] \right)^2 \quad (22)$$

where  $N_k$  is the number of observations we observe with the relevant  $(Z, T)$  pair and  $\hat{\mathbb{E}}$  is the empirical average. Note that this converges to the true  $\Sigma$  matrix under the assumption that the observations are all independent and as the number of observations increases to infinity for all observed  $(Z, T)$  pairs. Similarly, in the step where we **Estimate**  $\nu(Z)$ , we do so by calculating:

$$\hat{\nu}(Z) = \hat{\mathbb{E}}[T_i | Z_i = Z] \quad (23)$$

which agains converges to the true value of  $\nu(Z)$  as the number of observations for each value of the instrument increases. Thus, while nothing about the method described above necessitates a discrete instrument, the specific algorithm described here requires many observations for every value of the instrument.<sup>5</sup>

At this point, the algorithm branches depending on whether the user specifies an *Empirical Bayes* or *Full Bayes* approach. If they opt for an *Empirical Bayes* approach, the algorithm continuous to **Estimate Hyperparameters** by maximizing  $p(\theta | Y, T, Z)$  as described in the section above. Given these parameters, the algorithm then can **Calculate K**. To do so, it uses Equation (18) to calculate the covariances for  $\mu$  and  $\tau$  on a discrete grid of  $\eta$  values and then uses Remark 1 to transform these into the  $K_{\hat{Y}}$ ,  $K_{\hat{Y}, Y^{obs}}$ , and  $K_{Y^{obs}}$ , replacing the integrals implicit in Equation (8) with discrete approximations. Given the calculations of  $K$  – or really of  $K_{\hat{Y}}$ ,  $K_{\hat{Y}, Y^{obs}}$ , and

---

<sup>5</sup>An alternative approach is to treat the variance of the error term and the parameters of  $\nu$  as an additional hyperparameters, which would allow for more general settings.

---

**Algorithm 1:** Bayesian MTEs

---

**Data:**  $Y, T, Z$

**Output:**  $\mu_{\tilde{Y}}, \Sigma_{\tilde{Y}}$

**Pseudocode:**

Collapse Data;

Estimate  $\Sigma$ ;

Estimate  $\nu(Z)$ ;

**if** *Empirical Bayes* **then**

Estimate Hyperparameters;

Calculate  $K$ ;

Calculate  $\mu_{\tilde{Y}}$  and  $\Sigma_{\tilde{Y}}$ ;

**end**

**if** *Full Bayes* **then**

Sample Vector of Potential Hyperparameters;

**for**  $i \leftarrow 1$  to  $N_{samples}$  **do**

Accept or Reject  $\theta_i$ ;

**if** *Accept*  $\theta_i$  **then**

Calculate  $K$ ;

Calculate  $\mu_{\tilde{Y}}$  and  $\Sigma_{\tilde{Y}}$ ;

Save  $\mu_{\tilde{Y}}$  and  $\Sigma_{\tilde{Y}}$ ;

**end**

**end**

Calculate Overall  $\mu_{\tilde{Y}}$  and  $\Sigma_{\tilde{Y}}$ ;

**end**

Transform  $\mu_{\tilde{Y}}$  and  $\Sigma_{\tilde{Y}}$  to  $\hat{\tau}(\eta)$  and  $Var(\hat{\tau}(\eta))$ ;

---

$K_{Y^{obs}}$  – and  $\hat{\Sigma}$ , it then uses Equations (13) and (14) to Calculate  $\mu_{\hat{\gamma}}$  and  $\Sigma_{\hat{\gamma}}$ .

If the user instead chooses the *Full Bayes* approach, the algorithm then uses simple rejection sampling scheme to sample potential hyperparameters. Specifically, to **Sample Vector of Potential Hyperparameters** it randomly draws 10,000 potential values of  $\theta$  from the hyperprior distribution defined in the section above. For each potential vector of hyperparameters, it then determines whether to **Accept or Reject**  $\theta_i$  by calculating the marginal likelihood for this value of  $\theta_i$  using Equation (19), normalizing it by dividing the marginal likelihood by the maximum value of the marginal likelihood obtained over the 10,000 samples, and then accepting the value of  $\theta$  if (and only if) the normalized marginal likelihood is greater than the value of a random variable sampled  $U(0, 1)$ .<sup>6</sup> Such a sampling scheme is a relatively inefficient way to sample from the posterior, but it is sufficient for this algorithm given the small number of hyperparameters.

For each accepted vector of hyperparameters, it then proceeds as in the *Empirical Bayes* approach, e.g., the first step is to **Calculate**  $K$  and then to **Calculate**  $\mu_{\hat{\gamma}}$  and  $\Sigma_{\hat{\gamma}}$  as described above. Unlike the *Empirical Bayes* approach, however, it then needs to conclude by combining each of the resulting estimates to **Calculate Overall**  $\mu_{\hat{\gamma}}$  and  $\Sigma_{\hat{\gamma}}$ . For this, we can use the fact that the resulting posterior is a mixture of normally distributed random variables, which means there is a closed form solution for the mean and variance of the posterior. Specifically, the overall mean is the average of the posterior means for each value of  $\theta$ , while the overall variance is the average posterior variance plus the variance of the posterior means.<sup>7</sup>

Regardless of whether the user specified to use an *Empirical Bayes* or *Full Bayes* approach, the algorithm concludes with a step to **Transform**  $\mu_{\hat{\gamma}}$  and  $\Sigma_{\hat{\gamma}}$  to  $\hat{\tau}(\eta)$  and  $Var(\hat{\tau}(\eta))$ . This is done using Equation (4) and is necessary to transform the posteriors of  $y_0(\eta)$  and  $y_1(\eta)$  to the posterior of  $\tau(\eta)$ , which is generally the object of interest.

Finally, we note that the publicly available code uses the algorithm outlined above,

---

<sup>6</sup>To see that this approach works, note that we can draw from the hyperprior distribution  $p(\theta)$  and want to draw from the hyperposterior, i.e.,  $p(\theta|Y, ZT)$ . But since the hyperposterior is proportional to  $p(Y|\theta, Z, T) \cdot p(\theta)$ , we get that the ratio of the hyperposterior to the hyper prior is just the marginal likelihood, i.e.,  $\frac{p(\theta|Y, Z, T)}{p(\theta)} = p(Y|\theta, Z, T)$ .

<sup>7</sup>Note, however, that a mixture of Gaussians is not itself normally distributed, so we would need to further simulate the draws if we wanted to determine the distribution of the posterior rather than just the mean and variance.

but includes as its output some additional results, such as some of the graphs produced in Section V and measures of the average treatment effect, always taker average treatment effect, never taker average treatment effect, and the local average treatment effect. It also allows the user to input their own hyperprior and to specify if they care only about extrapolation, statistical, or frequentist uncertainty. See <https://github.com/isaacopper/BayesianMTEs> for more information about the code.

## V Empirical Example

We now explore how the method works in practice by focusing on a specific empirical example. Our main example will be the Oregon Health Insurance Experiment (OHIE), in which participating individuals were randomly assigned to be eligible or ineligible to enroll in Medicaid. See the OHIE website for more detail about the OHIE and links to the public data, and well as Finkelstein et al. (2012); Taubman et al. (2014); Finkelstein et al. (2016) for other work on the OHIE. We also provide additional examples via simulations for both binary instruments and continuous instruments in Appendix C.

We chose to use the OHIE for a handful of reasons. First and foremost, the data is publicly available and so interested readers can easily explore how our subjective choices (e.g., hyperpriors) impact the results. Second, the OHIE is a particularly interesting context for us to study. Not only does it provide some of the most compelling evidence on an important public policy question, but it had high levels of non-compliance; many of those that were randomly given eligibility did not enroll in Medicaid and many of those that were not randomly given eligibility gained eligibility in another way and so ended up enrolling in Medicaid. Finally, by using the same data as a previous study that used a linear extrapolation, namely Kowalski (2023), it is easy to compare the two approaches and understand the relative benefits of the two approaches. For that reason, we will focus on the same outcome as used in Kowalski (2023), namely the likelihood that an individual will go the emergency room (ER).

We start by illustrating how the data informs the plausible values of the hyperparameters. To do so, we take a slightly different approach than the one discusses in Section IV.B and instead of random sampling from the hyperposterior we calculate the marginal likelihood, i.e.,  $p(Y|\theta, Z, T)$ , for all values of  $\theta$  in a discrete grid of step-

size 0.1 with  $\log(l) \in [-3, 3]$  and  $\log(\sigma) \in [-3, 3]$ .<sup>8</sup> We also calculate the hyperprior, i.e.  $p(\theta)$  for each of these values, using the hyperprior specified in Equation (21). To help visualize the results, we then turn the marginal likelihood into a function of the lengthscale by choosing the value for  $\sigma$  that maximizes the marginal likelihood for each value of  $l$ .<sup>9</sup> We also do the same for the hyperprior and then combine these to produce a plot of the marginal distribution of the hyperposterior, i.e., the posterior as a function of  $l$ . We also do the same to plot the marginal likelihood, hyperprior, and hyperposterior as a function of  $\sigma$ .

The results are shown in Figure 2. The top two subfigures show the marginal likelihood of the hyperparameters in solid lines and the hyperpriors in dashed lines and the bottom two subfigures show the hyperposterior; the left two subfigures show the results for the lengthscale ( $l$ ) and the right two show the results for the scale ( $\sigma$ ). The main result is that Figure 2 highlights the fact that the lengthscale ( $l$ ) is not particularly well identified, while in contrast the scale hyperparameter ( $\sigma$ ) is relatively well identified. This can be seen in the fact that the marginal likelihood of the lengthscale does not have a well-defined peak – as seen in Figure 2a – while the scale does – as seen in Figure 2b. As a consequence, the hyperposterior of  $l$  – shown in Figure 2c – is more similar to the hyperprior of  $l$  than of the marginal likelihood, while the hyperposterior of  $\sigma$  – shown in Figure 2d – is more similar to the marginal likelihood of  $\sigma$  than to the hyperprior. Finally, we conclude by acknowledging that – at least in this empirical example – the proposed specification results in the hyperposterior of  $l$  being determined more by the researchers’ choice of the hyperprior more than the data; however, as we discuss more in Appendix B.A, a more diffuse prior often results in a smaller credible interval for most of the estimands rather than a larger one.

We next turn our attention to the estimands of interest, namely the MTE function  $\hat{\tau}(\eta)$  and various averages of the MTE function such as the overall average treatment effect (ATE), the always taker average treatment effect (ATATE), the never taker average treatment effect (NTATE), and the complier average treatment effect also known as the local average treatment effect (LATE). We start by initial using a single value of the hyperparameters: the maximum a posteriori (MAP) values, i.e.,


---

<sup>8</sup>In other words,  $\log(l) = -3 + 0.1k$  for  $0 \leq k \leq 60$  and  $\log(\sigma) = -3 + 0.1j$  for  $0 \leq j \leq 60$ .

<sup>9</sup>Formally, we plot  $p(Y|l, Z, T)$  as a function of  $l$  where  $p(Y|l, Z, T) = \max_{\log(\sigma) \in [-3, 1]} p(Y|\sigma, l, Y, Z, T)$ .




Figure 2: Bayesian Priors, Marginal Likelihood, and Posterior of the Hyperparameters



Note: The top two subfigures show the marginal likelihood of the hyperparameters in solid lines and the hyperpriors in dashed lines, while the bottom two figures show the hyperposterior in solid lines. The left two figures show the results for the lengthscale parameter ( $l$ ), while the right two figures show the result for the scale parameter ( $\sigma$ ); see Section IV.A for a discussion of the two hyperparameters. To illustrate the results on a two-dimensional graph, we show plots as a function of one hyperparameter while optimizing over the second. For example, in the top-left figure we show the marginal likelihood as a function of  $l$  by plotting  $p(Y|l, Z, T) = \max_{\sigma} p(Y|l, \sigma, Z, T)$ .

Figure 3: Random Functions via Empirical Bayes




Note: This figure shows ten random functions sampled from a Gaussian process with estimated hyperparameters. In Panel (a), the functions are drawn unconditionally while in Panel (b) we condition on the four observed moments.

the value of  $\theta$  that maximizes the  $p(\theta|Y, Z, T)$ .<sup>10</sup> This approach is often referred to as empirical Bayes approach and results in the following values for the hyperparameters:  $\log(l) = 0.11$  and  $\log(\sigma) = -1.97$  or  $l = 1.11$  and  $\sigma = 0.14$ .

Holding these hyperparameters fixed, we then simulate ten random functions  $y_1$  and  $y_0$ . These simulations are shown in Figure 3; Panel (a) shows ten random functions drawn without conditioning on any data, while panel (b) shows ten random functions drawn when conditioning on the observed four moments. While not a particularly subtle point, Figure 3 illustrates nicely that conditioning on the four observed moments has a large impact on the plausible functions, even if it does not fully pin down the entirety of the functions.

<sup>10</sup>Note that we choose the MAP value, rather than the value that maximizes the log marginal likelihood. These coincide under a very diffuse prior on the hyperparameters, however, for reasons we discuss above and in Appendix B.A we view it preferable to use an informed prior on the hyperparameters.

Figure 4: Posterior Mean and 95% CIs



Note: Panel (a) shows the posterior mean and 95% credible interval of the function  $y_0$  (in the red solid lines) and  $y_1$  (in the blue dashed lines). The black dots represent the estimated moments observed in the data. Panel (b) shows the posterior distribution of the MTE function, i.e.  $\tau(\eta)$ , with the solid indicating the posterior mean and the dashed lines indicating the 95% credible interval.

Figure 4a uses the above equations to calculate the posterior distribution of  $y_1$  and  $y_0$  on a 101 point grid. The red solid lines illustrate the posterior mean of  $y_0$  and the 95% credible interval, while the blue dashed lines show illustrate the posterior mean of  $y_1$  and the 95% CI. The black dots indicate the four estimated moments. Note that the posterior means come close – but do not go directly through – the four black dots and there is still uncertainty in the posterior distributions of the  $y$  functions at the point where the four moments are observed. This is because the four moments are estimated with error rather than being observed directly and so the mean of the posterior does not correspond exactly to the observed mean.<sup>11</sup> However, as would be expected, the posterior variance increases significantly away from the observed moments.

The posterior distributions of  $y_1$  and  $y_0$ , while suggestive, are mainly useful because they allow us to construct a posterior distribution of the marginal treatment effect (MTE) function. In particular, as illustrated in Equation (4) the MTEs can be approximated via a linear combination of four points on the curves  $y_1$  and  $y_0$ . The posterior of the MTE function is therefore also normally distributed and we can use Equation (4) to compute the posterior distribution of the MTE at the same 101 point grid used to estimate  $y_1$  and  $y_0$ . This is illustrated in Figure 4b, which shows that the effect of Medicaid enrollment on ER visits is higher for those more likely to enroll (if given eligibility) than those less likely to enroll. This is consistent with Kowalski (2023). As illustrated in the dashed lines, however, we cannot be particularly confident in these point estimates, with the 95% CIs spanning from an effect of approximately 0.15 to  $-0.15$  among those who are least likely to enroll in treatment.

We can similarly use Equation (4) to compute various average effects, such as the overall average treatment effect (ATE), always taker average treatment effect (ATATE), never taker average treatment effect (NTATE), and the local average treatment effect (LATE). While there is a lot of uncertainty in MTEs, we can be much more confident in the implied average effects. This is true even though (with the exception of the LATE) the average effects are unidentified and therefore require some extrapolation beyond the observed moments. After the RCT we have the most confidence in the LATE estimate – which requires no extrapolation beyond the ob-

---

<sup>11</sup>This depends on the choice of the prior; if we include in the kernel an additional linear term with infinite prior variance, the posterior means will go directly through the observed moments. See Opper and Özek (2023), for example.


served measures – and the least confidence in the NTATE estimate – which requires the most extrapolation. This result can be seen in Table 1, which shows that the standard deviation of the LATE posterior is approximately half that of the NTATE posterior. In addition as suggested by Figure 4b, the mean posterior of the ATATE is greater than the LATE, which is in turn greater than the NTATE. This can also be seen in Figure 5, which shows the prior distributions of the four estimands discussed above in blue and the posterior distributions in red; as can be seen, the observed data significantly changes the posterior distribution of even the unidentified estimands.

An important caveat is that results in the first two columns of Table 1 take the hyperparameter values as fixed. An alternative, and arguably preferable approach, is to incorporate uncertainty in the hyperparameters by integrating over the posterior distribution of hyperparameters. As discussed in Section IV.B, we therefore repeat analysis for a range of hyperparameters that are consistent with the data using a simple accept/reject algorithm. In doing so, we accepted approximately 20% of the 10,000 proposed values of the hyperparameters; for each accepted value, we can use the approach outlined above to generate posterior distributions of the MTE function as well as the LATE, ATE, ATATE, and NTATE. The resulting posterior is therefore a mixture of normally distributed random variables, which means there is a closed form solution for the mean and variance of the posterior. The results of this are shown in the final two columns of Table 1. Intuitively, the posterior standard deviations are mostly unchanged for the averages which require the least extrapolation from the observed moments – in particular, the ATATE and LATE – while the posterior standard deviations of the NTATE increases by 40% when accounting for uncertainty in the hyperparameters.


We conclude by using the results of Section III.B to better understand the sources of uncertainty in the posterior estimates. The results are shown in Table 2. In the four columns, we show the standard deviation of the posterior of four average effects: ATE, ATATE, LATE, and NTATE. Even the NTATE, which requires the most extrapolation away from the observed moments the statistical uncertainty is significantly larger than the extrapolation uncertainty. From a practical perspective, it means that increasing the sample size and/or decreasing the variance of the residual will significantly reduce the uncertainty of the resulting average treatment effects, even the ones that are theoretically unidentified. Note that the relative unimportance of extrapolation uncertainty in the resulting estimate of the NTATE, for example, stems

Figure 5: Bayesian Prior and Posterior Distributions of Four Estimands


(a) Average Treatment Effect (ATE)




(b) Complier Average Treatment Effect (LATE)



(c) Always Taker Average Treatment Effect (ATATE)



(d) Never Taker Average Treatment Effect (NTATE)



Note: The four subfigures show the prior distribution of the estimand of interest in blue and the posterior distribution in red.

Table 1: Posterior Means and Standard Deviations

	Empirical Bayes		Full Bayes	
	Mean	Std.	Mean	Std.
Avg. Treat Effect (ATE)	0.054	0.035	0.053	0.045
Always Taker Avg. Treat Effect (ATATE)	0.108	0.027	0.110	0.031
Local Avg. Treat Effect (LATE)	0.083	0.023	0.083	0.024
Never Taker Avg. Treat Effect (NTATE)	0.030	0.051	0.029	0.070

Note: This table shows the mean and standard deviation of the posterior distribution of the estimated effects. The first two columns estimate the value of the hyperparameters, while the last two columns integrates over the hyperposterior distribution. See Section IV.B for more discussion of the differences between the two approaches.

in part from the fact that the NTATE involves averaging  $\tau(\eta)$  over a relatively large range of  $\eta$  values, i.e.,  $NTATE = \mathbb{E}[\tau(\eta)|\eta \in (0.38, 1)]$  in the OHIE experiment. The extrapolation uncertainty is a higher fraction of the posterior variance of a single point on the MTE function, e.g.,  $\hat{\tau}(1)$  for example, than for the NTATE. This can be seen by comparing Figure 4 to Figure 10.

It’s worth emphasizing that the OHIE was much, much larger than most RCTs, with a sample size of more than 19,000 participants even when restricting to the Portland sample as we do. This, along with the fact that compliance rates were low, suggests that the relative importance of statistical uncertainty would be even larger for most other RCTs. To illustrate this, we consider the relative importance of the sources if the OHIE instead had a sample size of only 1,000. As can be seen, the statistical uncertainty increases – as would be expected – but the extrapolation uncertainty does not change; hence, the importance of statistical uncertainty increases relative to the extrapolation uncertainty when the sample size decreases.<sup>12</sup> For more discussion of how the uncertainty scales with the sample size, see Appendix B.B.

<sup>12</sup>The minor changes in the extrapolation uncertainty between the full sample and the sample of 1,000 in Table 2 are because the estimated cutoffs – and hence the extrapolation uncertainty – will vary slightly depending on the sample.

Table 2: Statistical vs. Extrapolation vs. Frequentist Uncertainty

	Full Sample			
	Full	Stat.	Extrap.	Freq.
Avg. Treat Effect (ATE)	0.035	0.031	0.015	0.025
Always Taker ATE (ATATE)	0.027	0.025	0.008	0.021
Local ATE (LATE)	0.023	0.023	0.000	0.021
Never Taker ATE (NTATE)	0.051	0.044	0.025	0.033
	N = 1,000			
	Full	Stat.	Extrap.	Freq.
Avg. Treat Effect (ATE)	0.066	0.064	0.016	0.036
Always Taker ATE (ATATE)	0.057	0.056	0.007	0.036
Local ATE (LATE)	0.058	0.058	0.000	0.037
Never Taker ATE (NTATE)	0.079	0.075	0.025	0.036

Note: This table shows the standard deviations of the posterior distributions. The definition of statistical uncertainty, abbreviated as “Stat.” – extrapolation uncertainty – abbreviated as “Extrap.” – and frequentist uncertainty – abbreviated as “Freq.” are in Section III.B. To ease the comparison, we use the same set of hyperparameters for all eight estimates, which are the hyperparameters that maximize the hyper-posterior in the full sample.



## VI Conclusion

This paper developed a Bayesian model that generates posterior distributions of the marginal treatment effects (MTEs) and hence of various estimates of interest, e.g., the average treatment effect (ATE), always taker average treatment effect (AT ATE), or never taker average treatment effect (NT ATE). By providing a principled approach to extrapolate from observed estimands, this model can help researchers generate plausible ranges for important and potentially policy-relevant (but unidentified) quantities of interest.

We conclude by noting that our focus here is on a simple model: one with a single binary treatment, a single binary instrument, and no covariates. In theory, it is simple to extend the model in Section II to include other covariates, i.e., we can simply include  $X_i$  in every conditional expectation and extend the GP covariances to be functions of both  $\eta$  and  $X$ . Even here, however, this raises important implementation questions about how to handle the new covariance functions. Namely, do we assume that the functions  $\tau(\eta, X)$  and  $\mu(\eta, X)$  are separably in  $\eta$  and  $X$  or allow for some interaction? If some interactions are allowed, how much interaction is allowed and how does the choice of hyperpriors reflect these decisions?

One can also start thinking of ways to extend the model in Section II to capture more complex settings – e.g., those with multiple or continuous treatments and multiple instruments – and/or to different research designs – e.g., designs that combine experimental and non-experimental variation or fuzzy regression discontinuity designs. Thus, while we view this paper as a useful method in and of itself, we also hope that it helps illustrate that utility of adding a hierarchical Bayesian model on top of traditional econometric models and of the relative ease with which the Gaussian process Bayesian model and generalized Roy models can work together.

## References

- Balke, Alexander and Judea Pearl**, “Bounds on Treatment Effects from Studies with Imperfect Compliance,” *Journal of the American Statistical Association*, 1997, 92 (439), 499–527.
- Bhattacharya, Jay, Azeem M. Shaikh, and Edward Vytlačil**, “Treatment Effect Bounds under Monotonicity Assumptions: An Application to Swan-Ganz Catheterization,” *American Economic Review: Papers and Proceedings*, 2008, 98 (2), 351–356.
- Brinch, Christian N., Magne Mogstad, and Matthew Wiswall**, “Beyond LATE with a Discrete Instrument,” *Journal of Political Economy*, 2017, 125 (4), 985–1039.
- Finkelstein, Amy, Sarah Taubman, Bill Wright, Mira Bernstein, Jonathan Gruber, Joseph P. Newhouse, Heidi Allen, Katherine Baicker, and the Oregon Health Study Group**, “The Oregon Health Insurance Experiment: Evidence from the First Year,” *Quarterly Journal of Economics*, 2012, 127 (3), 1057–1106.
- , – , **Heidi Allen, Bill Wright, and Katherine Baicker**, “Effect of Medicaid Coverage on ED Use - Further Evidence from Oregon’s Experiment,” *New England Journal of Medicine*, 2016, 375 (16), 1505–1507.
- Gechter, Michael and Rachael Meager**, “Combining Experimental and Observational Studies in Meta-Analysis: A Debiasing Approach,” 2022.
- Hastie, Trevor, Robert Tibshirani, and Jerome Friedman**, *The Elements of Statistical Learning*, Springer Series in Statistics, 2009.
- Heckman, James J.**, “Building Bridges Between Structural and Program Evaluation Approaches to Evaluating Policy,” *Journal of Economic Literature*, 2010, 48 (2), 356–398.
- **and Edward J. Vytlačil**, “Econometric Evaluation of Social Programs, Part I: Causal Models, Structural Models and Econometric Policy Evaluation,” in J. J. Heckman and E. E. Leamer, eds., *Handbook of Econometrics*, Vol. 6, Elsevier, 2007, chapter 70, pp. 4779–4874.

- **and** –, “Econometric Evaluation of Social Programs, Part II: Using the Marginal Treatment Effect to Organize Alternative Econometric Estimators to Evaluate Social Programs, and to Forecast Their Effects in New Environments,” in J. J. Heckman and E. E. Leamer, eds., *Handbook of Econometrics*, Vol. 6, Elsevier, 2007, chapter 71, pp. 4785–5143.
- **and Edward Vytlačil**, “Local Instrumental Variables and Latent Variable Models for Identifying and Bounding Treatment Effects,” *Proceedings of the National Academy of Sciences*, 1999, *96* (8), 4730–4734.
- **and** –, “Policy-Relevant Treatment Effects,” *American Economic Review*, 2001, *91* (2), 107–11.
- **and** –, “Structural Equations, Treatment Effects, and Econometric Policy Evaluation,” *Econometrica*, 2005, *73* (3), 669–738.
- Imbens, Guido W. and Joshua D. Angrist**, “Identification and Estimation of Local Average Treatment Effects,” *Econometrica*, 1994, *62* (2), 467–475.
- Kline, Patrick and Christopher R. Walters**, “On Heckits, LATE, and Numerical Equivalence,” *Econometrica*, 2019, *87* (2).
- Kowalski, Amanda**, “Reconciling Seemingly Contradictory Results from the Oregon Health Insurance Experiment and the Massachusetts Health Reform,” *Review of Economics and Statistics*, 2023, *105* (3), 646–664.
- Manski, Charles F.**, “Nonparametric Bounds on Treatment Effects,” *American Economic Review*, 1990, *80* (2), 319–323.
- Meager, Rachael**, “Understanding the Average Impact of Microcredit Expansion: A Bayesian Hierarchical Analysis of Seven Randomized Experiments,” *American Economic Journal: Applied Economics*, 2019, *11* (1), 57–91.
- , “Aggregating Distributional Treatment Effects: A Bayesian Hierarchical Analysis of the Microcredit Literature,” *American Economic Review*, 2022, *112* (6), 1818–1847.
- Mogstad, Magne, Andres Santos, and Alexander Torgovitsky**, “Using Instrumental Variables for Inference about Policy Relevant Treatment Parameters,” *Econometrica*, 2018, *86* (5), 1589–1619.

**Opper, Isaac M. and Umut Özek**, “A Global Regression Discontinuity Design: Theory and Application to Grade Retention Policies,” 2023.

**Poirier, Dale J.**, “Revising Beliefs in Nonidentified Models,” *Econometric Theory*, 1998, 14.

**Rasmussen, Carl Edward and Christopher K. I. Williams**, *Gaussian Processes for Machine Learning*, The MIT Press, 2006.

**Taubman, Sarah, Heidi Allen, Bill Wright, Katherine Baicker, Amy Finkelstein, and the Oregon Health Study Group**, “Medicaid Increases Emergency Department Use: Evidence from Oregon’s Health Insurance Experiment,” *Science*, 2014, 343 (6168), 263–268.

## A Proofs

**Remark 1.** Under the the Bayesian hierarchical model defined in Section II and Assumption 1,  $\tilde{y}(t, \eta)$  as defined in Equation (7) also follows a mean-zero Gaussian process with a covariance function – denoted  $k_{\tilde{y}}$  – that depends on  $k_{\mu}(\eta, \eta' | \theta_{\mu})$  and  $k_{\tau}(\eta, \eta' | \theta_{\tau})$ . In particular, we have that:

$$k_{\tilde{y}}((t, \eta), (t', \eta') | \theta_{\mu}, \theta_{\tau}) = \begin{cases} \mathbb{E}[k_{\mu}(\tilde{\eta}, \tilde{\eta}' | \theta_{\mu}) + k_{\tau}(\tilde{\eta}, \hat{\eta} | \theta_{\tau}) | \tilde{\eta} \leq \eta, \tilde{\eta}' \leq \eta'] & \text{if } t = t' = 1 \\ \mathbb{E}[k_{\mu}(\tilde{\eta}, \tilde{\eta}' | \theta_{\mu}) | \tilde{\eta} > \eta, \tilde{\eta}' > \eta'] & \text{if } t = t' = 0 \\ \mathbb{E}[k_{\mu}(\tilde{\eta}, \tilde{\eta}' | \theta_{\mu}) | \tilde{\eta} > \eta, \tilde{\eta}' \leq \eta'] & \text{if } t = 0 \neq t' \\ \mathbb{E}[k_{\mu}(\tilde{\eta}, \tilde{\eta}' | \theta_{\mu}) | \tilde{\eta} \leq \eta, \tilde{\eta}' > \eta'] & \text{if } t = 1 \neq t' \end{cases} \quad (8)$$

*Proof.* We first show that under the model specified in Section II and Assumption 1, we can infer that the Gaussian process for both  $\tau$  and  $\mu$  are continuous processes. To do so, we note that:

$$\begin{aligned} \mathbb{E}\left[(\mu(\eta) - \mu(\eta'))^4\right] &= 12 \cdot (k_{\mu}(\eta, \eta | \theta_{\mu}) - k_{\mu}(\eta, \eta' | \theta_{\mu}))^2 \\ &\leq C(\eta - \eta')^2 \end{aligned}$$

where  $C$  is a constant. The first equality stems from the fact that  $\mu(\eta) - \mu(\eta')$  is distributed normally and the inequality comes from the assumption that  $k_{\mu}$  is Lipschitz continuous. From this expression, we can use the Kolmogorov continuity theorem to infer that  $\mu$  is a continuous process. Note that the fact that  $\mu(\eta)$  can be assumed to be continuous implies that  $y_0(\eta) = \frac{1}{1-\eta} \int_{\eta}^1 \mu(\tilde{\eta}) d\tilde{\eta}$  can be arbitrarily approximated by a finite sum of jointly Gaussian variables. In the same way, we can show that  $\tau$  is a continuous process and that  $y_1(\eta)$  can be arbitrarily approximated by a finite sum of jointly Gaussian variables.

We can then show that  $\tilde{y}(t, \eta)$  is itself a Gaussian process. For this, consider any finite linear combination  $\sum a_k \tilde{y}(t_k, \eta_k)$ . As highlighted above, we have that each  $\tilde{y}(t_k, \eta_k)$  can be arbitrarily approximated by a finite sum of jointly Gaussian variables and so  $\sum a_k \tilde{y}(t_k, \eta_k)$  can be arbitrarily approximated by a finite sum of jointly Gaussian variables and is therefore Gaussian. Thus,  $\tilde{y}$  is a Gaussian process.

We therefore need only show that the covariance of  $\tilde{y}(t, \eta)$  accords to the definition above, which is mostly just algebra. For example, consider two points  $\tilde{y}(1, \eta)$  and

$\tilde{y}(1, \eta')$ . From the definition of  $\tilde{y}$ , we get that:

$$\begin{aligned}
\text{Cov}(\tilde{y}(1, \eta), \tilde{y}(1, \eta')) &= \left( \frac{1}{N} \lim_{N \rightarrow \infty} \sum_{i=0}^N \mu(\eta \frac{i}{N}) + \tau(\eta \frac{i}{N}) \right) \cdot \left( \frac{1}{N} \lim_{N \rightarrow \infty} \sum_{i=0}^N \mu(\eta' \frac{i}{N}) + \tau(\eta' \frac{i}{N}) \right) \\
&= \lim_{N \rightarrow \infty} \sum_{i=0}^N \left( \mu(\eta \frac{i}{N}) + \tau(\eta \frac{i}{N}) \right) \cdot \sum_{i=0}^N \left( \mu(\eta' \frac{i}{N}) + \tau(\eta' \frac{i}{N}) \right) \\
&= \lim_{N \rightarrow \infty} \sum_{i=0}^N \mu(\eta \frac{i}{N}) \cdot \sum_{i=0}^N \mu(\eta' \frac{i}{N}) + \lim_{N \rightarrow \infty} \sum_{i=0}^N \tau(\eta \frac{i}{N}) \cdot \sum_{i=0}^N \tau(\eta' \frac{i}{N}) \\
&= \mathbb{E}[k_\mu(\tilde{\eta}, \tilde{\eta}' | \theta_\mu) | \tilde{\eta} \leq \eta, \tilde{\eta}' \leq \eta'] + \mathbb{E}[k_\tau(\tilde{\eta}, \tilde{\eta}' | \theta_\mu) | \tilde{\eta} \leq \eta, \tilde{\eta}' \leq \eta']
\end{aligned}$$

□

The only somewhat subtle point in here is the third equality, which uses the fact that  $\tau(\eta)$  and  $\mu(\eta)$  are assumed to be independent GPs. The covariance functions when  $t \neq 1$  and/or  $t' \neq 1$  are derived similarly.

**Remark 2.** *The Bayesian posterior of  $\tilde{Y}$  given the observed data:*

$$\tilde{Y} | Y^{obs} \sim N(\mu_{\tilde{Y}}, \Sigma_{\tilde{Y}}) \quad (12)$$

where

$$\mu_{\tilde{Y}} = K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}} + \Sigma)^{-1} Y^{obs} \quad (13)$$

$$\Sigma_{\tilde{Y}} = K_{\tilde{Y}} - K_{\tilde{Y}, Y^{obs}} (K_{Y^{obs}} + \Sigma)^{-1} K'_{\tilde{Y}, Y^{obs}} \quad (14)$$

*Proof.* This is a simple application of conditional multivariate normal distributions. □

**Remark 3.** *Define  $\Sigma_{\tilde{Y}}$  as in Equation (14) and  $\Sigma_{extrap}$  and  $\Sigma_{stat}$  as in Equations (15)-(16). Then we have the following:*

- Both  $\Sigma_{extrap}$  and  $\Sigma_{stat}$  are positive semi-definite matrices.
- If  $\Sigma = 0$ , then  $\Sigma_{stat} = 0$ .
- Let  $\tau$  be some estimand of interest and define  $\tilde{Y}$  to be the set of observations needed to calculate  $\tau$ . Then  $\Sigma_{extrap} = 0$  if  $\tau$  is identified given the observed data.

- *Extrapolation and statistical uncertainty combine to equal the overall uncertainty, e.g.,  $\Sigma_{\tilde{Y}} = \Sigma_{extrap} + \Sigma_{stat}$*

*Proof.* For the first statement, we get that  $\Sigma_{stat}$  is a positive semi-definite matrix using the fact that  $K_{Y^{obs}}^{-1} - (K_{Y^{obs}} + \Sigma)^{-1}$  is a positive semi-definite matrix. This, in turn, stems from the fact that  $A - B$  is positive semi-definite, then  $B^{-1} - A^{-1}$  is positive semi-definite and  $K_{Y^{obs}}^{-1} - (K_{Y^{obs}} + \Sigma)^{-1}$  is positive definite from the fact that  $(K_{Y^{obs}} + \Sigma) - K_{Y^{obs}} = \Sigma$  is positive definite. The fact that  $\Sigma_{extrap}$  is positive semi-definite comes from the fact that it is the covariance matrix of a conditional multivariate normal.

The second statement is immediately clear from the definition of  $\Sigma_{stat}$  and the fourth statement can be shown using simple arithmetic.

The only somewhat challenging proof is the third statement and here the challenge comes from developing an appropriate definition of identification rather than from the resulting proof. To do so, we will distinguish between an estimand being non-parametrically identified and one that is estimated parametrically. First, we consider some estimand  $\tau$ , which – as discussed in Section II.A – we can write as  $\omega' \tilde{Y}$  for some weights  $\omega$  and conditional moments  $\tilde{Y} = [y_1(\bar{\eta}), y_1(\underline{\eta}), y_0(\bar{\eta}), y_0(\underline{\eta})]'$ , e.g., Equation (4). Then if  $\tau$  is non-parametrically identified in the conventional frequentist sense, it must be the case that (at least eventually) we observe measures for each of the four conditional moments necessary to calculate  $\hat{\tau}$ .<sup>13</sup> In the model, we can write that concisely by stating that  $\{\underline{\eta}, \bar{\eta}\} \in Range(\nu)$  and, from this, it follows that  $K_{\tilde{Y}} = K_{Y^{obs}} = K_{\tilde{Y}, Y^{obs}}$  and so  $\Sigma_{extrap} = 0$ .<sup>14</sup>

We next consider the case in which  $\tau$  is identified parametrically, rather than non-parametrically. To do so, we can write our model – as discussed in Section II.D – by specifying that  $\tau(\eta) = \phi_\tau(\eta)' \beta$  and  $\mu(\eta) = \phi_\mu(\eta)' \alpha$  for some (unknown) parameters  $\alpha$  and  $\beta$  and some (known) vectors  $\phi_\tau$  and  $\phi_\mu$  that are basis expansions of  $\eta$ , and a prior on  $\alpha$  and  $\beta$  such that  $k_\tau(\eta, \eta') = \phi(\eta)' \Sigma_\beta \phi(\eta')$  and  $k_\mu(\eta, \eta') = \phi(\eta)' \Sigma_\alpha \phi(\eta')$ . For

<sup>13</sup>Admittedly, with work one can create a counterexample; for example, consider a model indexed by  $N$  in which  $Y^{obs, N} = [\hat{y}_{1, N}(\bar{\eta} + \frac{\Delta}{N}), \hat{y}_{1, N}(\underline{\eta} + \frac{\Delta}{N}), \hat{y}_{0, N}(\bar{\eta} + \frac{\Delta}{N}), \hat{y}_{0, N}(\underline{\eta} + \frac{\Delta}{N})]'$ . Then if each of the  $\hat{y}$  estimates converge to the true conditional moments as  $N \rightarrow \infty$ , the  $\tau$  would be non-parametrically identified in the conventional frequentist sense even though we never (quite) observe measures for each of the four conditional moments necessary to calculate  $\hat{\tau}$ . Examples such as this could likely be handled by relaxing the equality size in our definition to something akin to “nearly identical,” but we will leave such technicalities for future work.

<sup>14</sup>Technically, if there are other  $\eta \in Range(\nu)$  we can make this statement true by adding additional observations to  $\tilde{Y}$  with a weight of zero.

notation, let  $\Phi$  denote the stacked values of  $\phi(\eta)$  that correspond to  $Y^{obs}$ ,  $\tilde{\Phi}$  denote the stacked values of  $\phi(\eta)$  that correspond to  $\tilde{Y}$ , and  $\Omega$  be the implied prior (e.g., a block diagonal with  $\Sigma_\beta$  and  $\Sigma_\alpha$  as diagonals). Then, as discussed in Rasmussen and Williams (2006) among others, we can write:

$$K_{Y^{obs}} = \Psi' \Psi \quad (24)$$

$$K_{\tilde{Y}} = \tilde{\Psi}' \tilde{\Psi} \quad (25)$$

$$K_{\tilde{Y}, Y^{obs}} = \tilde{\Psi}' \Psi \quad (26)$$

where  $\Psi = \Omega^{1/2} \Phi$  and  $\tilde{\Psi} = \Omega^{1/2} \tilde{\Phi}$ . We can then write:

$$K_{\tilde{Y}, Y^{obs}} K_{Y^{obs}}^{-1} K'_{\tilde{Y}, Y^{obs}} = (\tilde{\Psi}' \Psi) (\Psi' \Psi)^{-1} (\tilde{\Psi}' \Psi)' \quad (27)$$

Next letting  $A^+$  denote the Moore-Penrose inverse of  $A$ , we can re-write this as:

$$K_{\tilde{Y}, Y^{obs}} K_{Y^{obs}}^{-1} K'_{\tilde{Y}, Y^{obs}} = (\tilde{\Psi}' \Psi) (\Psi^+ \Psi^+)' (\tilde{\Psi}' \Psi)' \quad (28)$$

$$= \tilde{\Psi}' (\Psi \Psi^+) (\Psi^+ \Psi^+)' \tilde{\Psi} \quad (29)$$

The key step is to realize that if  $\tau$  is parametrically identified, then  $\Psi$  has full row rank. For example, if  $\tau(\eta)$  and  $\mu(\eta)$  are assumed to be polynomials of degree  $K$ , then  $\Psi$  having full row rank is equivalent to the assumption that  $\nu(Z)$  takes at least  $K + 1$  values. This is important, because if  $\Psi$  has full row rank we get that  $\Psi \Psi^+ = \Psi^+ \Psi^+ = I$ , where  $I$  is the identity matrix. Thus,  $\tau$  being parametrically identified implies that:

$$K_{\tilde{Y}, Y^{obs}} K_{Y^{obs}}^{-1} K'_{\tilde{Y}, Y^{obs}} = \tilde{\Psi}' \tilde{\Psi} \quad (30)$$

Since  $K_{\tilde{Y}}$  also equals  $\tilde{\Psi}' \tilde{\Psi}$  – see Equation (25) – it immediately follows that  $\Sigma_{extrap} = 0$  if  $\tau$  is parametrically identified.  $\square$

**Remark 4.** Define  $\Sigma_{stat}$  as in Equation (16) and  $\Sigma_{freq}$  as in Equation (17). Then if  $\Sigma \neq 0$ , we have that  $\Sigma_{stat} - \Sigma_{freq}$  is a positive definite matrix.



*Proof.* Using the definitions of  $\Sigma_{stat}$  and  $\Sigma_{freq}$ , we can start by noting that:

$$\begin{aligned} \Sigma_{stat} - \Sigma_{freq} &= \\ & K_{\tilde{Y}, Y_{obs}} (K_{Y_{obs}}^{-1} - (K_{Y_{obs}} + \Sigma)^{-1}) K'_{\tilde{Y}, Y_{obs}} - K_{\tilde{Y}, Y_{obs}} (K_{Y_{obs}} + \Sigma)^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} K'_{\tilde{Y}, Y_{obs}} = \\ & K_{\tilde{Y}, Y_{obs}} \left[ (K_{Y_{obs}}^{-1} - (K_{Y_{obs}} + \Sigma)^{-1}) - (K_{Y_{obs}} + \Sigma)^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} \right] K'_{\tilde{Y}, Y_{obs}} \end{aligned}$$

Since  $K_{\tilde{Y}, Y_{obs}}$  has full column rank, it then follows that if:

$$(K_{Y_{obs}}^{-1} - (K_{Y_{obs}} + \Sigma)^{-1}) - (K_{Y_{obs}} + \Sigma)^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1}$$

is positive definite, then so is  $\Sigma_{stat} - \Sigma_{freq}$ . With some algebra, we get that:

$$\begin{aligned} (K_{Y_{obs}}^{-1} - (K_{Y_{obs}} + \Sigma)^{-1}) &= \left[ K_{Y_{obs}}^{-1} (K_{Y_{obs}} + \Sigma) - I \right] (K_{Y_{obs}} + \Sigma)^{-1} \\ &= \left[ I + K_{Y_{obs}}^{-1} \Sigma - I \right] (K_{Y_{obs}} + \Sigma)^{-1} \\ &= K_{Y_{obs}}^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} \end{aligned}$$

where  $I$  corresponds to the identity matrix. We can therefore write:

$$\begin{aligned} (K_{Y_{obs}}^{-1} - (K_{Y_{obs}} + \Sigma)^{-1}) - (K_{Y_{obs}} + \Sigma)^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} &= \\ K_{Y_{obs}}^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} - (K_{Y_{obs}} + \Sigma)^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} \end{aligned}$$

We will then use the fact that if  $B^{-1} - A^{-1}$  is positive definite, then  $A - B$  is positive definite and so aim to show that:

$$\left[ (K_{Y_{obs}} + \Sigma)^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} \right]^{-1} - \left[ K_{Y_{obs}}^{-1} \Sigma (K_{Y_{obs}} + \Sigma)^{-1} \right]^{-1}$$

is positive definite. Using the rules of matrix inversion and matrix multiplication, we

can then get that:

$$\begin{aligned}
\left[ (K_{Y^{obs}} + \Sigma)^{-1} \Sigma (K_{Y^{obs}} + \Sigma)^{-1} \right]^{-1} - \left[ K_{Y^{obs}}^{-1} \Sigma (K_{Y^{obs}} + \Sigma)^{-1} \right]^{-1} &= \\
(K_{Y^{obs}} + \Sigma) \Sigma^{-1} (K_{Y^{obs}} + \Sigma) - (K_{Y^{obs}} + \Sigma) \Sigma^{-1} K_{Y^{obs}} &= \\
(K_{Y^{obs}} \Sigma^{-1} + I) (K_{Y^{obs}} + \Sigma) - (K_{Y^{obs}} \Sigma^{-1} + I) K_{Y^{obs}} &= \\
(K_{Y^{obs}} \Sigma^{-1} + I) \Sigma &= \\
K_{Y^{obs}} + \Sigma &
\end{aligned}$$

which is positive definite since both  $K_{Y^{obs}}$  and  $\Sigma$  are positive definite. □

## B Additional Results using the OHIE

### B.A Results under Different Hyperparameters

As discussed in the Section V the hyperparameters – and particularly the lengthscales – are not well identified. Thus, our preferred approach is to integrate over the posterior distribution of the the hyperparameters. In practice, we do so via an accept/reject algorithm which give a large number of plausible hyperparameters. For each hyperparameter, we use the method described above to estimate the mean and variance of the resulting posteriors. For our main results, we then combine these estimates by calculating the overall mean and variance of the full posterior; here, we further explore how the mean and variance of the posteriors depend on the hyperparameters.


We start by first showing the mean and variance of the Gaussian posterior of the ATATE, LATE, and NTATE for each hyperparameter drawn from the hyperposterior. The results are shown in Figure 6, which shows that the posterior mean and variance of the (unidentified) ATATE and NTATE depend more on the value of the hyperparameter than the (identified) LATE.

How the variances depend on the hyperparameters is illustrated in Figure 7a, which shows that over the range of our hyperprior the posterior variances are decreasing with the lengthscale.<sup>15</sup> The reasoning is clear when considering the random

---

<sup>15</sup>As before, we show the results as a function of  $l$  by showing the posterior variance under the hyperparameters  $l$  and  $\sigma^*(l)$  where  $\sigma^*(l)$  is the value of  $\sigma$  that maximizes the hyperposterior for  $l$ , i.e.,  $\sigma^*(l) = \arg \max_{\sigma} p(l, \sigma | Y, T, Z)$ .

Figure 6: Mean/Variance Estimates for Each Set of Hyperparameters Sampled




Note: Each mark shows the mean and variance of the posterior distribution for three of the estimates of interest – the always treated average treatment effect (ATATE); the complier average treatment effect (LATE); and the never treatment average treatment effect (NTATE) – with each dot representing the estimates for a particular set of hyperparameters randomly drawn from the hyperposterior using an accept/reject algorithm. To keep the graph from being too cluttered, we do not include the overall average treatment effect (ATE); however, the ATE is simply a weighted average of the three estimands shown and so naturally the cluster of dots lies in between the three clusters shown.

Figure 7: Posterior Variances as a Function of the Lengthscales

(a)  $\log(l) \in (-2, 2)$

(b)  $\log(l) \in (-5, 5)$



Note: This figure shows the posterior variances of the four main estimates of interest as a function of the lengthscale indicated on the x-axis, with the value of  $\sigma$  being the one that maximizes the hyperposterior for  $l$ , i.e.,  $\sigma^*(l) = \arg \max_{\sigma} p(l, \sigma | Y, T, Z)$ . The four estimands shown are: the always treated average treatment effect (ATATE), the average treatment effect (ATE); the complier average treatment effect (LATE); and the never treatment average treatment effect (NTATE). The two panels differ only in the range of  $l$  that is shown.


functions presented in Figure 1 – for large lengthscales, the only realistic functions are (nearly) linear ones and so the two observed points are sufficient to pin down the entire function, while for small lengthscales the functions could be highly non-linear and so there is large amounts of uncertainty about how the functions appear away from the observed points. Note that the relationship between the lengthscale and the posterior variances are not monotonic and for very short lengthscales the estimands tend to decrease, as illustrated in Figure 7b. This is because for short enough lengthscales the oscillations of MTE function are likely to average out when integrating over a range of  $\eta$  values, as we do for the never taker average treatment effect. It is also worth noting again that the assumed lengthscale does not have a meaningful effect on the variance of the identified LATE and only matters for the unidentified estimands.

Finally, we can also look at how the assumed standard deviation of the lengthscale’s hyperprior affects the posterior variance. As shown in Figure 8, the results depend in large part on whether one uses chooses to use an empirical Bayes or full Bayes approach. In Figure 8a, we see that increasing the standard deviation of the lengthscale’s hypeprior tends to reduce the estimated posterior variance. In contrast, when using the full Bayes approach, the posterior variance tends to be maximed around a value of 1; however, in the full Bayes approach the prior SD of the lengthscale does not have a major impact on the estimated posterior variance. To see this, note that in both Figure 8a and Figure 8b, we normalize the posterior variance so it equals one for the largest estimated posterior variance. From the scale of the y-axis, we can see that the choice of the hyperprior’s standard deviation doesn’t affect the posterior variance by more than 10% for any of the estimands except for the always taker average treatment effect, which stems from the fact that in our empirical example the always takers are just a sliver of the population. In contrast, as implicit in the scale of the y-axis of Figure 8a, the assumed standard deviation of the hyperprior has a relatively large impact on the estimated posterior variance if one uses an empirical Bayes approach.

## B.B Simulating the Asymptotic Uncertainty

In Section V we show the mean and variance of the posterior distributions when the sample size is 1,000 and when the sample size is 19,000. In Figure 9, we show how the posterior variance for the four estimands of interest – the ATE, ATATE, LATE, and

Figure 8: Posterior Variances as a Function of the Lengthscale Hyperprior Standard Deviation



Note: This figure shows normalized posterior variances of the four main estimates of interest as a function of the assumed standard deviation of the hyperprior of the lengthscale; it uses the hyperprior of  $\sigma$  as defined in Section IV.A. We normalize the posterior variance by dividing the implied posterior variance by the maximum posterior variance for each estimand. The four estimands shown are: the always treated average treatment effect (ATATE), the average treatment effect (ATE); the complier average treatment effect (LATE); and the never treatment average treatment effect (NTATE). The vertical black dashed line corresponds to the standard deviation used for the main empirical results. The two panels differ on whether one uses an empirical Bayes approach or a full Bayes approach, as discussed in Section IV.B.

NTATE – adjusts as the sample size increases. To do so, we randomly sample with replacement from the original dataset, varying whether the number of observations sampled is: 100; 500; 1,000; 5,000; 10,000; 100,000; or 1,000,000. To ensure that the results are not driven by idiosyncracies in the random sample, we repeat the process 10 times for each sample size and show the average posterior variance over those 10 simulations.

As can be seen in Figure 9, the log posterior variance of the LATE scales linearly with the log sample size. This reflects that the LATE requires no extrapolation and so all the uncertainty stems from statistical uncertainty. Of course, from the law of large numbers the uncertainty in the moment averages is asymptotically proportional to the inverse of the sample size, hence the log posterior variance of the LATE is proportional to the log of the sample size. In contrast, the other averages do require extrapolation and so the linear relationship between the log posterior variance and the log sample size no longer holds. Instead, the posterior variances asymptotes to some value above zero; this value is the extrapolation uncertainty we define in Section III.B. As seen in Figure 9, however, for most reasonable sample sizes, uncertainty in the true values of the observed moments is large enough that increasing the sample size meaningfully reduces the posterior variance.


We can also consider the asymptotic behavior in more detail by studying the extrapolation uncertainty, as defined in Section III.B. To do so, we reproduce Figure 4 while using only the extrapolation uncertainty instead of total uncertainty, which provides a window into how the resulting estimates asymptote. (This assumes that the observed moments remain the same as more data is added.) The results are illustrated in Figure 10 below.

## C Simulations

### C.A An Example of a Continuous Instrument with Limited Support

In our main example, we consider the case in which there is a single binary instrument. The method can also be used in cases with a continuous (or near continuous) instruments. For example, one can easily imagine applying it to judge/examiner IV designs. Here, we often find that there are a large number of cases in which all the

Figure 9: Asymptotic Variances




Note: This figure shows the variance of the posterior distribution for the four main estimates of interest and how that varies with the sample size. Both panels show the same data and simulations, with the only difference being that the y-axis on panel (a) uses a log-scale. The four estimands shown are: the always treated average treatment effect (ATATE), the average treatment effect (ATE); the complier average treatment effect (LATE); and the never treatment average treatment effect (NTATE).




Figure 10: Posterior Mean and 95% CIs – Extrapolation Uncertainty Only

(a) Conditional Moment Functions



(b) Marginal Treatment Effects



Note: Here, we reproduce Figure 4, while ignoring uncertainty in the estimated moments. The Panel (a) shows the posterior mean and 95% credible interval of the function  $y_0$  (in the red solid lines) and  $y_1$  (in the blue dashed lines). The black dots represent the estimated MTE moments observed in the data. Panel (b) shows the posterior distribution of the MTE function, i.e.  $\tau(\eta)$ , with the solid indicating the posterior mean and the dashed lines indicating the 95% credible interval.


judges/examiners agree, with a limited set of cases in which the decision depends on which judge is assigned the case. In our model, we can express this as the researcher observing  $y_1(\eta)$  and  $y_0(\eta)$  at a large number of points, all of which fall in some range  $(\underline{\eta}, \bar{\eta}) \in (0, 1)$ . We can therefore use the Bayesian MTE model to derive estimates of what the impact would be if, for example, we made the most lenient judge even more lenient or the most strict judge even more strict. This would be important if we were considering a major policy change, for example, that would change the behavior of all judges or examiners.

To give a sense of how the model would handle such a case, we conducted a simple simulation in which individuals are randomly assigned to one of twenty judges. The judges have different levels on leniency, but all choose to convict anywhere from 20% to 40% of cases, e.g.,  $\nu(Z_i) \in \{0.20, 0.21, 0.22, \dots, 0.38, 0.39\}$ . We then determine  $\tau(\eta)$  and  $\mu(\eta)$  by drawing from a mean-zero Gaussian process with a squared-exponential covariance function with  $\log(l) = 0$  and  $\log(\sigma) = -.2$ . Given the two functions, each individual's outcome is then generated according to Section II.A, with  $\epsilon_i \sim N(0, 1)$ .

The results are shown in Figure 11, which highlight that the method can be used in instances where the instrument is not a single binary instrument. In fact, as we discuss in the next subsection, in many ways it is easier to apply the model in this can: with a continuous instrument it is much easier to identify the hyperparameters of the Gaussian process than when there is a single binary instrument. This also means that the decision of whether to use an empirical Bayes or full Bayes approach is less important where there is a (nearly) continuous instrument than when there is a binary instrument.

That said, we should also note that most judge IV designs include a range of controls in their preferred specifications, especially a number of fixed effects that remove potentially endogenous sorting of cases to districts, time slots, etc. As mentioned in the conclusion, it is theoretically simple to extend the model in Section II to include other covariates, but doing so raises some additional implementation questions that we do not address in this paper. In addition, as discussed briefly in the paper the algorithm outlined in Section IV.B assumes that the function  $\nu(Z_i)$  and the matrix  $\Sigma$  are known with enough precision that we can treat them as known; such assumptions are often plausible in cases with a binary, but more suspect in cases where the instrument (or instruments) are not binary. As discussed briefly in the conclusion, we view these as an important avenues for future research, but will leave it for other

Figure 11: Posterior Mean and 95% CIs – Continuous Instrument with Limited Support



Note: Here, we reproduce Figure 4 using a simulation in which individuals are randomly assigned to one of two instruments (e.g., judges or examiners) with  $\nu(Z_i) \in \{0.20, 0.21, 0.22, \dots, 0.38, 0.39\}$ . Panel (a) shows the posterior mean and 95% credible interval of the function  $y_0$  (in the red solid lines) and  $y_1$  (in the blue dashed lines). The black dots represent the estimated moments observed in the data. Panel (b) shows the posterior distribution of the MTE function, i.e.  $\tau(\eta)$ , with the solid indicating the posterior mean and the dashed lines indicating the 95% credible interval.

papers to explore in depth.


## C.B Identifying the Hyperparameters

As we discuss in Section IV.B an important decision for researchers is whether to use an empirical Bayes or full Bayes approach. The results in Figure 2, and in particular the fact that the marginal likelihood of  $l$  in the OHIE example, suggest that the lengthscale is not well-identified. Interpreting this result is a bit challenging, however, since we do not know the “true” lengthscale to judge the results against. Here we further explore the identification of the lengthscale via a simulation, in which we can judge the marginal likelihood against the true lengthscale we use in the simulations.

In this simulation, we assume that  $\tau(\eta)$  and  $\mu(\eta)$  are generated via a mean-zero Gaussian process with a squared-exponential covariance function with  $\log(l) = 0$  and  $\log(\sigma) = -.2$ . For each of 100 simulations, we draw new functions  $\tau(\eta)$  and  $\mu(\eta)$ , randomly assign individuals to the instrument, and then assign individuals to the treatment depending on their (randomly determined) value of  $\eta_i$  and which instrument they were assigned to. Each of the 100,000 individuals’ outcome is then generated according to Section II.A, with  $\epsilon_i \sim N(0, 0.1)$ , so there is little uncertainty in the true values of the observed moments.

We then consider three types of instruments: a binary instrument with  $\nu(Z_i) \in \{.25, .75\}$ ; a “continuous instrument with partial support” in which  $\nu(Z_i) \in \{0.1, 0.15, \dots, 0.5, 0.55\}$ ; and a “continuous instrument with full support” in which  $\nu(Z_i) \in \{0.025, 0.075, \dots, 0.925, 0.975\}$ . For each simulation, we compute the marginal likelihood for a range of values of  $l$  and  $\sigma$ , plot the marginal likelihood as a function of  $l$  by choosing the value of  $\sigma$  for each  $l$  with the highest marginal likelihood, and then normalize the estimated marginal likelihoods so that the highest value is equal to one. We then average this marginal likelihood over all of the simulations, which we show in Figure 12. As can be seen, when there is a binary instrument the marginal likelihood is quite flat for a range of lengthscales; in contrast, when one has a nearly continuous instrument – and especially one with a large range of support – the lengthscale is more precisely identified. This implies both that an empirical Bayes approach is likely to give similar results as the full Bayes approach and that the specification of the hyperprior will have a smaller impact on the resulting estimates when there is a continuous instrument than when there is a binary one.

Figure 12: Identifying the Lengthscale



Note: To illustrate the results on a two-dimensional graph, we show the marginal likelihood as a function of  $l$  by calculating  $p(Y|l, Z, T) = \max_{\sigma} p(Y|l, \sigma, Z, T)$  for each of the simulations. We then normalize the calculations by dividing the resulting marginal likelihood by the maximum value of the marginal likelihood and the plot the average value and the plot the average value over the 100 simulations. The instruments are defined as follows: the binary instrument has  $\nu(Z_i) \in \{.25, .75\}$ ; the continuous instrument with partial support has  $\nu(Z_i) \in \{0.1, 0.15, \dots, 0.5, 0.55\}$ ; and the continuous instrument with full support has  $\nu(Z_i) \in \{0.025, 0.075, \dots, 0.925, 0.975\}$ .